RE-BVS – Piemonte Repository

Sfoglia per AUTORE
PEDRAZZOLI P
Collezione AO Ordine Mauriziano

Items : 6

Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2024 Jul 2;73(9):161. doi: 10.1007/s00262-024-03741-2.

2024
AO Ordine Mauriziano

Messina C; Catalano M; Roviello G; Gandini A; Maruzzo M; De Giorgi U; Pedrazzoli P; Sbrana A; Zucal PA; Masini C; Naglieri E; Procopio G; Milella M; Catalano F; Fratino L; Pipitone S; Ricotta R; Panni S; Mollica V; Soraru M; Prati V; Atzori F; Di Napoli M; Messina M; Morelli F; Prati G; Nole F; Malgeri A; Tudini M; et alii...

Italian oncologists and vaccinations against infectious diseases: Results of a survey of the Italian Association of Medical Oncology. in Tumori / Tumori. 2024 Feb;110(1):60-68. doi: 10.1177/03008916231191547. Epub 2023 Aug 10.

2024
AO Ordine Mauriziano

Di Maio M; Pedrazzoli P; Silvestris N; Brunello A; Lasagna A; Cinieri S;

Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM). in ESMO open / ESMO Open. 2023 Jun;8(3):101215. doi: 10.1016/j.esmoop.2023.101215. Epub 2023 Apr 3.

2023
AO Ordine Mauriziano

Pedrazzoli P; Lasagna A; Cassaniti I; Piralla A; Squeri A; Bruno R; Sacchi P; Baldanti F; Di Maio M; Beretta GD; Cinieri S; Silvestris N;

Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM). in ESMO open / ESMO Open. 2022 Aug;7(4):100548. doi: 10.1016/j.esmoop.2022.100548. Epub 2022 Jul 16.

2022
AO Ordine Mauriziano

Pedrazzoli P; Lasagna A; Cassaniti I; Ferrari A; Bergami F; Silvestris N; Sapuppo E; Di Maio M; Cinieri S; Baldanti F;

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The ?-Meet-URO analysis. in Frontiers in oncology / Front Oncol. 2022 Sep 23;12:955501. doi: 10.3389/fonc.2022.955501. eCollection 2022.

2022
ASL Cuneo 2
AO Ordine Mauriziano

Nolè F; Prati G; Morelli F; Messina M; Caffo O; Di Napoli M; Atzori F; Soto Parra HJ; Prati V; Cortellini A; Sorarù M; Santoni M; Massari F; Panni S; Ricotta R; Sabbatini R; Fratino L; Boccardo F; Milella M; Procopio G; Carella C; Fantinel E; Zucali PA; Galli L; Pedrazzoli P; De Giorgi U; Maruzzo M; Santini D; Stellato M; et alii...

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). in Therapeutic advances in medical oncology / Ther Adv Med Oncol. 2021 May 18;13:17588359211019642. doi: 10.1177/17588359211019642. eCollection 20

2021
AO Ordine Mauriziano

Bersanelli M; Casadei C; Pierantoni F; Roviello G; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Messina C; Messina M; Pignata S; Atzori F; Stellato M; Soto Parra HJ; Prati V; Santoni M; Cortellini A; Sorarù M; Mollica V; Panni S; Ricotta R; Baldessari C; Fratino L; Tomasello L; Merler S; Procopio G; Naglieri E; Masini C; et alii...